Revenue Recognition and Accounts Receivable Revenue Disaggregation (Table) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Disaggregation of Revenue [Line Items]
Net sales	$ 3,653.5	$ 3,719.1
Brands
Disaggregation of Revenue [Line Items]
Net sales	2,309.1	2,420.3
Generics
Disaggregation of Revenue [Line Items]
Net sales	1,344.4	1,298.8
Lipitor
Disaggregation of Revenue [Line Items]
Net sales	388.9	417.9
Norvasc
Disaggregation of Revenue [Line Items]
Net sales	176.3	202.7
Lyrica ®
Disaggregation of Revenue [Line Items]
Net sales	114.2	144.3
Viagra ®
Disaggregation of Revenue [Line Items]
Net sales	100.7	115.0
EpiPen® Auto-Injectors
Disaggregation of Revenue [Line Items]
Net sales	80.2	95.8
Celebrex ®
Disaggregation of Revenue [Line Items]
Net sales	72.2	88.8
Effexor ®
Disaggregation of Revenue [Line Items]
Net sales	59.4	64.6
Zoloft ®
Disaggregation of Revenue [Line Items]
Net sales	58.0	56.5
Creon ®
Disaggregation of Revenue [Line Items]
Net sales	75.0	72.7
Xalabrands
Disaggregation of Revenue [Line Items]
Net sales	42.5	46.7
Amitiza ®
Disaggregation of Revenue [Line Items]
Net sales	33.0	36.6
Xanax ®
Disaggregation of Revenue [Line Items]
Net sales	34.5	39.7
Dymista ®
Disaggregation of Revenue [Line Items]
Net sales	48.2	53.2
Yupelri ®
Disaggregation of Revenue [Line Items]
Net sales	55.2	47.0
Developed Markets Segment | Brands
Disaggregation of Revenue [Line Items]
Net sales	1,178.8	1,232.0
Developed Markets Segment | Generics
Disaggregation of Revenue [Line Items]
Net sales	986.6	938.4
Greater China | Brands
Disaggregation of Revenue [Line Items]
Net sales	541.8	562.4
Greater China | Generics
Disaggregation of Revenue [Line Items]
Net sales	2.1	2.2
Japan, Australia and New Zealand Segment | Brands
Disaggregation of Revenue [Line Items]
Net sales	184.1	190.3
Japan, Australia and New Zealand Segment | Generics
Disaggregation of Revenue [Line Items]
Net sales	133.7	151.9
Emerging Markets Segment | Brands
Disaggregation of Revenue [Line Items]
Net sales	404.4	435.6
Emerging Markets Segment | Generics
Disaggregation of Revenue [Line Items]
Net sales	222.0	206.3
Operating Segment | Developed Markets Segment
Disaggregation of Revenue [Line Items]
Net sales	2,165.4	2,170.4
Operating Segment | Greater China
Disaggregation of Revenue [Line Items]
Net sales	543.9	564.6
Operating Segment | Japan, Australia and New Zealand Segment
Disaggregation of Revenue [Line Items]
Net sales	317.8	342.2
Operating Segment | Emerging Markets Segment
Disaggregation of Revenue [Line Items]
Net sales	$ 626.4	$ 641.9